Transitional Care Medication Safety and Medical Liability: Closing the Chasm

过渡护理药物安全和医疗责任:弥合鸿沟

基本信息

  • 批准号:
    8015943
  • 负责人:
  • 金额:
    $ 29.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2011-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Effective risk management strategies that assure accurate transfer of medication information, improve patient safety and minimize medical liability during care transitions when patients discharge from the hospital to home care, are virtually nonexistent. Medication errors are the most prevalent adverse event following hospital discharge (Greenwald, Denham, & Jack, 2007); subsequently, these errors trigger malpractice claims when patients are harmed (Rothschild et al., 2002).There is a critical need to proactively link medication risk management to emerging transitional care models. The overall objective of this application is to improve medication safety and quality of care during the hospital to community transition, thereby improving patient outcomes and reducing adverse events and costs, including medical liability. When funded, the interdisciplinary team of nurses, pharmacists, nurse attorneys, a physician and a health policy economist will investigate two specific aims. First, the team will evaluate antecedent, structure, process, and outcome factors associated with medication discrepancies, adverse events, and medical liability during hospital to community transitions within a complex health care system. Statistical analyses combined with systematic review to evaluate the medical liability risk associated with ADRs when applied to statutory, regulatory and appellate case law will be completed. Second, the team will design best practice risk management strategies that can be integrated into transitional care. Using a sensemaking conceptual framework, focus groups comprised of stakeholders, including patients, health care providers, health plan administrators and attorneys, will be asked to reflect on, or make sense of, the medication discrepancy and medical liability data. Evidence based risk management strategies to maximize medication safety during hospital to community care transitions can then be designed, and successfully implemented. The proposed planning grant is significant because it will elucidate the actual legal risk associated with medication discrepancies during the transition from hospital to the community, and, it will identify risk management strategies to improve patient safety while minimizing medical liability. Combined, these outcomes are expected to serve as a blueprint for health care systems to proactively integrate medication risk management strategies into emerging transitional care models. Health policy changes that will require continuity of care for most, if not all patients, are imminent. As such, developed risk management strategies can subsequently be tested, replicated and disseminated to improve patient medication safety thereby reducing adverse events and medical liability. Patient outcomes will be improved and lower overall health care costs will be realized. Upon successful completion, the feasibility of integrating medication risk management efforts into transitional comprehensive, rather than episodic care, models to assure patient safety, quality, and cost-effectiveness while reducing medical liability will be demonstrated. PUBLIC HEALTH RELEVANCE: This planning grant is intended to engage all stakeholders in a thoughtful, thorough and productive effort to fundamentally advance medication safety science, reduce adverse events and minimize medical liability, by providing health systems with a quality improvement blueprint to use when implementing hospital to community care transition models. In so doing, this grant addresses AHRQ's national effort to combat medical errors and improve patient safety. Subsequently, developed risk management strategies can be tested, replicated and disseminated to improve medication safety for patients; patient outcomes will be improved and lower overall health care costs will be realized.
描述(由申请人提供):实际上不存在有效的风险管理策略,以确保准确传输药物信息、提高患者安全并在患者出院到家庭护理的护理过渡期间最大程度地减少医疗责任。用药错误是出院后最常见的不良事件(Greenwald、Denham 和 Jack,2007 年);随后,当患者受到伤害时,这些错误会引发医疗事故索赔(Rothschild 等,2002)。迫切需要主动将药物风险管理与新兴的过渡护理模式联系起来。该应用程序的总体目标是提高医院向社区过渡期间的用药安全和护理质量,从而改善患者的治疗效果并减少不良事件和成本,包括医疗责任。一旦获得资助,由护士、药剂师、护士律师、医生和卫生政策经济学家组成的跨学科团队将调查两个具体目标。首先,该团队将评估复杂的医疗保健系统内医​​院向社区过渡期间与药物差异、不良事件和医疗责任相关的前因、结构、过程和结果因素。将完成统计分析与系统审查相结合,以评估适用于法定、监管和上诉判例法时与 ADR 相关的医疗责任风险。其次,团队将设计可纳入过渡护理的最佳实践风险管理策略。使用意义建构概念框架,由患者、医疗保健提供者、健康计划管理者和律师等利益相关者组成的焦点小组将被要求反思或理解药物差异和医疗责任数据。然后可以设计并成功实施基于证据的风险管理策略,以最大限度地提高医院到社区护理过渡期间的用药安全。拟议的规划拨款意义重大,因为它将阐明从医院到社区过渡期间与药物差异相关的实际法律风险,并且将确定风险管理策略,以提高患者安全,同时最大限度地减少医疗责任。综合起来,这些结果预计将成为医疗保健系统的蓝图,以主动将药物风险管理策略整合到新兴的过渡性护理模式中。卫生政策的变化迫在眉睫,需要为大多数(如果不是全部)患者提供持续的护理。因此,制定的风险管理策略随后可以进行测试、复制和传播,以提高患者用药安全,从而减少不良事件和医疗责任。患者的治疗效果将得到改善,总体医疗保健成本也将降低。成功完成后,将证明将药物风险管理工作整合到过渡性综合而非间歇性护理模型中的可行性,以确保患者安全、质量和成本效益,同时减少医疗责任。 公共健康相关性:这项规划拨款旨在让所有利益相关者参与深思熟虑、彻底和富有成效的努力,通过为卫生系统提供质量改进蓝图,在实施医院到社区护理过渡模式时使用,从根本上推进药物安全科学,减少不良事件并最大限度地减少医疗责任。这笔赠款旨在支持 AHRQ 在全国范围内打击医疗差错和改善患者安全的努力。随后,可以测试、复制和传播已制定的风险管理策略,以提高患者的用药安全;患者的治疗效果将得到改善,总体医疗保健成本也将降低。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Cindy Lou Corbett其他文献

Cindy Lou Corbett的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Cindy Lou Corbett', 18)}}的其他基金

Chronic Care Management Model Translation to Multimorbid Aging Adults at FQHCs
将慢性护理管理模式转化为 FQHC 的多病老年人
  • 批准号:
    8506930
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Medication Intervention in Transitional Care to Optimize CKD Outcomes & Costs
过渡期护理中的药物干预可优化 CKD 结局
  • 批准号:
    8232548
  • 财政年份:
    2011
  • 资助金额:
    $ 29.88万
  • 项目类别:
Medication Intervention in Transitional Care to Optimize CKD Outcomes & Costs
过渡期护理中的药物干预可优化 CKD 结局
  • 批准号:
    8338869
  • 财政年份:
    2011
  • 资助金额:
    $ 29.88万
  • 项目类别:

相似国自然基金

CarE06介导朱砂叶螨对甲氰菊酯对映体代谢抗性形成差异机制
  • 批准号:
    CSTB2023NSCQ-MSX0916
  • 批准年份:
    2023
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
棉铃虫羧酸酯酶CarE001G在杀虫剂代谢和抗性中的作用及机制
  • 批准号:
    U1903111
  • 批准年份:
    2019
  • 资助金额:
    57 万元
  • 项目类别:
    联合基金项目
棉铃虫羧酸酯酶CarE001C定向进化及突变酶的结构与功能研究
  • 批准号:
    31201517
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

AutoPharmacist: Automated Medication Monitoring System in Primary Care
AutoPharmacist:初级保健中的自动药物监测系统
  • 批准号:
    10100250
  • 财政年份:
    2024
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Collaborative R&D
Patient-Driven Medication Safety Learning Laboratory in Care Transitions
护理转变中患者驱动的药物安全学习实验室
  • 批准号:
    10769211
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Enhancing Hypnotic Medication Discontinuation in Primary Care through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
通过监督药物逐渐减量和数字认知行为失眠治疗,加强初级保健中催眠药物的停药
  • 批准号:
    10736443
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
RECORDGATE: unlocking the power of medication records to enable every aspect of digital health & care to be joined-up
RECORDGATE:释放药物记录的力量,实现数字健康的各个方面
  • 批准号:
    10047184
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Collaborative R&D
Virtual MOUD Treatment: Virtual Point-of-Care Toxicology Testing to Accompany Virtual Medication Assisted Treatment for Opioid Use Disorder
虚拟 MOUD 治疗:虚拟护理点毒理学测试伴随阿片类药物使用障碍的虚拟药物辅助治疗
  • 批准号:
    10316571
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
Effects of Medicaid Managed Care on Medication Assisted Treatment Use and Health Outcomes among Pregnant Women with Opioid Use Disorder
医疗补助管理式护理对阿片类药物使用障碍孕妇的药物辅助治疗使用和健康结果的影响
  • 批准号:
    10517956
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
EHR usability and usefulness, perceived missed nursing care and medication errors in critical care
EHR 可用性和实用性、感知的错过护理和重症监护中的用药错误
  • 批准号:
    10670851
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
EHR usability and usefulness, perceived missed nursing care and medication errors in critical care
EHR 可用性和实用性、感知的错过护理和重症监护中的用药错误
  • 批准号:
    10503493
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
Drug-related problems in persons with cognitive impairment and dementia in primary-care based memory clinics: Effectiveness of medication reviews
初级保健记忆诊所中认知障碍和痴呆症患者的药物相关问题:药物审查的有效性
  • 批准号:
    460067
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了